Literature DB >> 21572779

Inhibiting the akt pathway in cancer treatment: three leading candidates.

Walter Alexander.   

Abstract

Entities:  

Year:  2011        PMID： 21572779      PMCID： PMC3086120     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  2 in total

Review 1.  Akt inhibitors in clinical development for the treatment of cancer.

Authors:  Sumanta Kumar Pal; Karen Reckamp; Hua Yu; Robert A Figlin
Journal:  Expert Opin Investig Drugs       Date:  2010-09-16       Impact factor: 6.206

2.  Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.

Authors:  Irene M Ghobrial; Aldo Roccaro; Fangxin Hong; Edie Weller; Nancy Rubin; Renee Leduc; Meghan Rourke; Stacey Chuma; Antonio Sacco; Xiaoying Jia; Feda Azab; Abdel Kareem Azab; Scott Rodig; Diane Warren; Brianna Harris; Lyuba Varticovski; Peter Sportelli; Xavier Leleu; Kenneth C Anderson; Paul G Richardson
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531
  2 in total
  9 in total

Review 1.  Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies.

Authors:  Kim M Keppler-Noreuil; Victoria E R Parker; Thomas N Darling; Julian A Martinez-Agosto
Journal:  Am J Med Genet C Semin Med Genet       Date:  2016-11-18       Impact factor: 3.908

2.  Suppression of Foxo1 activity and down-modulation of CD62L (L-selectin) in HIV-1 infected resting CD4 T cells.

Authors:  Benjamin Trinité; Chi N Chan; Caroline S Lee; Saurabh Mahajan; Yang Luo; Mark A Muesing; Joy M Folkvord; Michael Pham; Elizabeth Connick; David N Levy
Journal:  PLoS One       Date:  2014-10-16       Impact factor: 3.240

3.  Cudraflavone C Induces Tumor-Specific Apoptosis in Colorectal Cancer Cells through Inhibition of the Phosphoinositide 3-Kinase (PI3K)-AKT Pathway.

Authors:  Hsien-Chuen Soo; Felicia Fei-Lei Chung; Kuan-Hon Lim; Veronica Alicia Yap; Tracey D Bradshaw; Ling-Wei Hii; Si-Hoey Tan; Sze-Jia See; Yuen-Fen Tan; Chee-Onn Leong; Chun-Wai Mai
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

4.  Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression.

Authors:  Marion Le Grand; Raphael Berges; Eddy Pasquier; Marie-Pierre Montero; Laurence Borge; Alice Carrier; Sophie Vasseur; Veronique Bourgarel; Duje Buric; Nicolas André; Diane Braguer; Manon Carré
Journal:  Sci Rep       Date:  2017-03-23       Impact factor: 4.379

5.  Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR inhibitors.

Authors:  Ting Tao; Hui Shi; Meng Wang; Antonio R Perez-Atayde; Wendy B London; Alejandro Gutierrez; Bernardo Lemos; Adam D Durbin; A Thomas Look
Journal:  J Exp Med       Date:  2020-10-05       Impact factor: 14.307

Review 6.  FAK inhibitors as promising anticancer targets: present and future directions.

Authors:  Muhamad Mustafa; Amer Ali Abd El-Hafeez; Dalia A Abdelhafeez; Dalia Abdelhamid; Yaser A Mostafa; Pradipta Ghosh; Alaa M Hayallah; Gamal El-Din A Abuo-Rahma
Journal:  Future Med Chem       Date:  2021-08-03       Impact factor: 4.767

7.  ROS-mediated EB1 phosphorylation through Akt/GSK3β pathway: implication in cancer cell response to microtubule-targeting agents.

Authors:  Marion Le Grand; Amandine Rovini; Veronique Bourgarel-Rey; Stephane Honore; Sonia Bastonero; Diane Braguer; Manon Carre
Journal:  Oncotarget       Date:  2014-05-30

Review 8.  Targeting CD8 T-Cell Metabolism in Transplantation.

Authors:  Michelle Yap; Sophie Brouard; Claire Pecqueur; Nicolas Degauque
Journal:  Front Immunol       Date:  2015-10-23       Impact factor: 7.561

9.  Using machine learning algorithms to identify genes essential for cell survival.

Authors:  Santosh Philips; Heng-Yi Wu; Lang Li
Journal:  BMC Bioinformatics       Date:  2017-10-03       Impact factor: 3.169
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.